Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells

Cancer Science

Volumn 97, Issue 9, 2006, Pages 952-960

  Orsolic, Nada ^a,c   Golemovic, Mirna ^a   Quintás Cardama, Alfonso ^a   Scappini, Barbara ^a   Manshouri, Taghi ^a   Chandra, Joya ^b   Basic, Ivan ^c   Giles, Francis ^a   Kantarjian, Hagop ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPHOSTIN; ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; CASPASE 3; CASPASE 7; CBL PROTEIN; CRK LIKE PROTEIN; IMATINIB; PROTEIN BCL 2; SUPEROXIDE; TYRPHOSTIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ADAMANTANE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; HYDROQUINONES; INHIBITORY CONCENTRATION 50; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; TYROSINE;

EID: 33746610204     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00269.x     Document Type: Article

References (30)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. New Engl J Med 1999; 341: 164-72.
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-30.
3. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.
4. Beran M, Cao X, Estrov Z et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190 000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998; 4: 1661-72.
5. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-8.
6. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001; 344: 1031-7.
7. Kantarjian HM, Talpaz M. Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias. Seminars Oncol 2001; 28: 9-18.
8. Marcucci G, Perrotti D, Caligiuri MA. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res 2003; 9: 1333-7, Clin Cancer Res 2003; 9: 1248 -52.
9. Scappini B, Onida F, Kantarjian HM et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 2002; 94: 2653-62.
10. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA. Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 1994; 5: 213-22.
11. Kaur G, Sausville EA. Altered physical state of p210bcr-abl in tyrphostin AG957-treated K562 cells. Anticancer Drugs 1996; 7: 815-24.
12. Svingen PA, Tefferi A, Kottke TJ et al. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 2000; 6: 237-49.
13. Mow BM, Chandra J, Svingen PA et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002; 99: 664-71.
14. Losiewicz MD, Kaur G, Sausville EA. Different early effects of tyrphostin AG957 and geldanamycins on mitogen-activated protein kinase and p210 cbl phosphorylation in anti CD-3-stimatinibulated T-lymphoblasts. Biochem Pharmacol 1999; 57: 281-9.
15. Urbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochem Pharmacol 2002; 63: 689-92.
16. Chandra J, Hackbarth J, Le S et al. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 2003; 102: 4512-19.
17. Yu C, Rahmani M, Almenara J, Sausville EA, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene 2003; 23: 1364-76.
18. Chandra J, Tracy J, Loegering D et al. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood 2006; 107: 2501-6.
19. Shanafelt TD, Lee YK, Bone ED et al. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood 2005; 105: 2099-106.
20. Dasmahapatra G, Rahmani M, Dent P et al. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood 2006; 107: 232-40.
21. Dasmahapatra G, Nguyen TK, Dent P et al. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk Res 2006 Feb. 13; [Epub ahead of print].
22. Yu C, Rahmani M, Almenara J et al. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene 2004; 23: 1364-76.
23. Beran M, Pisa P, O'Brien S et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993; 53: 3603-10.
24. Andersson BS, Beran M, Pathak S, Goodacre A, Barlogie B, McCredie KB. Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern. Cancer Genet Cytogenetics 1987; 24: 335-43.
25. Wang C, Curtis JE, Minden MD, McCulloch EA. Expression of a retinioic acid receptor gene in myeloid leukemia cells. Leukemia 1981; 3: 264-9.
26. Papayannopoulou T, Nakamoto B, Kurachi S, Tweeddale M, Messner H. Surface antigenic profile and globin phenotype of two new human erythroleukemia lines: Characterization and interpretations. Blood 1988; 72: 1029-38.
27. Scappini B, Gatto S, Onida F et al. Changes associated with the development of resistance to STI571 in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 2004; 100: 1459-71.
28. Ricci C, Scappini B, Divoky V et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 2002; 62: 5995-8.
29. Avramis IA, Christodoulopoulos G, Suzuki A et al. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother Pharm 2002; 50: 479-89.
30. Avramis IA, Laug WE, Sausville EA, Avramis VI. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemoth Pharm 2003; 52: 307-18.